MYH9 and gastric cancer: The downregulated MYH9 protein impairs the recruitment of the deubiquitinase USP2, promoting the degradation of β-conjugated proteins and ultimately inhibiting EMT signaling, cell migration, invasion, and metastasis, indicating its potential as a therapeutic target in gastric cancer (Liu J. et al., 2020).